Literature DB >> 1280987

Interferon treatment for hepatitis B-associated membranous glomerulonephritis in two Chinese children.

S N Wong1, E C Yu, A S Lok, K W Chan, Y L Lau.   

Abstract

Two Chinese boys, aged 3.5 and 5 years, developed nephrotic syndrome and were chronic carriers of hepatitis B virus surface antigen (HBsAg) and hepatitis B virus e antigen (HBeAg). Renal biopsy showed membranous glomerulonephritis and liver biopsy showed chronic persistent hepatitis. They were given interferon-alpha-2a at a dose of 5 MU/m2 on alternate days for 12 and 16 weeks after 2 years of persistent nephrotic syndrome. Patient 1 showed complete remission and resolution of hepatosplenomegaly, but his serum remained positive for HBsAg, HBeAg and hepatitis B virus DNA. Patient 2 showed only a transient clinical response and seroconversion from HBeAg to anti-HBe status. Although not always successful, interferon treatment should be considered in severe persistent nephrotic states, since there is at present no satisfactory treatment for this form of glomerulonephropathy.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1280987     DOI: 10.1007/BF00873997

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  21 in total

1.  A randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. The Hepatitis Interventional Therapy Group.

Authors:  R P Perrillo; E R Schiff; G L Davis; H C Bodenheimer; K Lindsay; J Payne; J L Dienstag; C O'Brien; C Tamburro; I M Jacobson; R Sampliner; D Feit; J Lefkowitch; M Kuhns; C Meschievitz; B Sanghvi; J Albrecht; A Gibas
Journal:  N Engl J Med       Date:  1990-08-02       Impact factor: 91.245

2.  Hepatitis B surface antigen associated nephrotic syndrome.

Authors:  A T Elidrissy; M B Abdurrahman; S Ramia; J B Lynch
Journal:  Ann Trop Paediatr       Date:  1988-09

3.  Improvement of hepatitis B-associated glomerulonephritis after antiviral combination therapy.

Authors:  R A de Man; S W Schalm; A J van der Heijden; F W ten Kate; E D Wolff; R A Heijtink
Journal:  J Hepatol       Date:  1989-05       Impact factor: 25.083

4.  Randomized, controlled trial of recombinant human alpha-interferon in patients with chronic hepatitis B.

Authors:  J H Hoofnagle; M Peters; K D Mullen; D B Jones; V Rustgi; A Di Bisceglie; C Hallahan; Y Park; C Meschievitz; E A Jones
Journal:  Gastroenterology       Date:  1988-11       Impact factor: 22.682

5.  The therapeutic dilemma of the usage of corticosteroid in patients with membranous nephropathy and persistent hepatitis B virus surface antigenaemia.

Authors:  K N Lai; J S Tam; H J Lin; F M Lai
Journal:  Nephron       Date:  1990       Impact factor: 2.847

6.  Hepatitis B virus associated membranous glomerulonephritis.

Authors:  J Wiggelinkhuizen; C Sinclair-Smith; L M Stannard; H Smuts
Journal:  Arch Dis Child       Date:  1983-07       Impact factor: 3.791

7.  Loss of HBsAg with interferon therapy in chronic hepatitis B virus infection.

Authors:  G J Alexander; J Brahm; E A Fagan; H M Smith; H M Daniels; A L Eddleston; R Williams
Journal:  Lancet       Date:  1987-07-11       Impact factor: 79.321

8.  Hepatitis B surface antigenemia in North American children with membranous glomerulonephropathy. Southwest Pediatric Nephrology Study Group.

Authors: 
Journal:  J Pediatr       Date:  1985-04       Impact factor: 4.406

9.  Long-term follow-up in a randomised controlled trial of recombinant alpha 2-interferon in Chinese patients with chronic hepatitis B infection.

Authors:  A S Lok; C L Lai; P C Wu; E K Leung
Journal:  Lancet       Date:  1988-08-06       Impact factor: 79.321

10.  Membranous nephropathy in 52 hepatitis B surface antigen (HBsAg) carrier children in Taiwan.

Authors:  H C Hsu; C Y Wu; C Y Lin; G J Lin; C H Chen; F Y Huang
Journal:  Kidney Int       Date:  1989-12       Impact factor: 10.612

View more
  11 in total

1.  Renal adverse effects of interferon-alpha.

Authors:  Slobodan Jankovic
Journal:  Drug Saf       Date:  2005       Impact factor: 5.606

2.  Treatment of hepatitis B virus-associated glomerulonephritis: a meta-analysis.

Authors:  Yu Zhang; Jian-Hua Zhou; Xiao-Ling Yin; Feng-Yu Wang
Journal:  World J Gastroenterol       Date:  2010-02-14       Impact factor: 5.742

Review 3.  What is the actual management of a child with membranous glomerulopathy associated with chronic hepatitis B?

Authors:  M C Chiu
Journal:  Pediatr Nephrol       Date:  1996-04       Impact factor: 3.714

4.  Interferon treatment in hepatitis B virus-associated membranous glomerulopathy.

Authors:  S Kavukçu; G Başdemir; Y Eroğlu; M Türkmen; F Eser; B Büyükgebiz
Journal:  Pediatr Nephrol       Date:  1995-08       Impact factor: 3.714

5.  Nephrotic syndrome, was found to be positive for hepatitis B surface antigen.

Authors:  M C Chiu
Journal:  Pediatr Nephrol       Date:  1996-02       Impact factor: 3.714

6.  Interferon treatment of hepatitis B-associated membranous glomerulonephritis and nephrotic syndrome.

Authors:  N Giboa; D Neigut
Journal:  Pediatr Nephrol       Date:  1993-06       Impact factor: 3.714

7.  Hepatitis B and Renal Disease.

Authors:  Tak Mao Chan
Journal:  Curr Hepat Rep       Date:  2010-04-14

8.  A case of adefovir-induced membranous nephropathy related to hepatitis B caused by lamivudine-resistant virus after liver transplant due to Byler's disease.

Authors:  Shinich Ebata; Seiji Hashimoto; Akira Suzuki; Masanori Ito; Tomochika Maoka; Yasunobu Ishikawa; Toshio Mochizuki; Takao Koike
Journal:  Clin Exp Nephrol       Date:  2012-08-22       Impact factor: 2.801

Review 9.  Viral hepatitis in children with renal disease.

Authors:  G V Gregorio; A P Mowat
Journal:  Pediatr Nephrol       Date:  1994-10       Impact factor: 3.714

10.  The clinical course of hepatitis B virus-associated nephropathy.

Authors:  R D Gilbert; J Wiggelinkhuizen
Journal:  Pediatr Nephrol       Date:  1994-02       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.